Target intelligence / Profile preview

Complement-Dependent Cytotoxicity (None)

Target
None
Molecular classification
Immune effector function, Mechanism
01

Overview

Complement-dependent cytotoxicity (CDC) is a biological mechanism by which the immune system destroys target cells, such as bacteria, virus-infected cells, or tumor cells. This process is initiated when antibodies—primarily IgG1, IgG3, and IgM—isotypes—bind to antigens on the surface of a target cell. The Fc region of these antibodies then interacts with C1q, the first component of the classical complement pathway. This triggers a cascade that leads to the assembly of the membrane attack complex (MAC), resulting in pore formation in the cell membrane and subsequent lysis or death of the target cell.

02

Mechanism of action

Antibody-mediated complement activation leading to MAC formation and cell lysis

03

Biological functions

Immune responseCell deathTarget cell lysis
04

Disease associations

CancerInfection
05

Safety considerations

Off-target cell lysisInflammatory response
06

Interacting drugs

Rituximab

2 more in the full profile.

Beyond the preview

Go deeper on Complement-Dependent Cytotoxicity (None).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Complement-Dependent Cytotoxicity (None).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call